• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Cohen Jacob D.

    3/20/26 5:00:28 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MGRX alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cohen Jacob D.

    (Last)(First)(Middle)
    C/O MANGOCEUTICALS, INC.
    17130 N. DALLAS PARKWAY, SUITE 240

    (Street)
    DALLAS TEXAS 75248

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    MANGOCEUTICALS, INC. [ MGRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirectorX10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/16/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock200,000D(1)
    Common Stock605,000D(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (right to buy)$16.503/16/2026D(3)50,000 (4)09/01/2027Common Stock50,000$00D(1)
    Stock Option (right to buy)$0.4503/16/2026A(3)50,000 (4)09/01/2027Common Stock50,000$050,000D(1)
    Stock Option (right to buy)$4.803/16/2026D(3)83,33312/28/202312/28/2028Common Stock83,333$00D(1)
    Stock Option (right to buy)$0.4503/16/2026A(3)83,33312/28/202312/28/2028Common Stock83,333$083,333D(1)
    Stock Option (right to buy)$2.303/16/2026D(3)2,000,000 (5)09/09/2035Common Stock2,000,000$00D(1)
    Stock Option (right to buy)$0.4503/16/2026A(3)2,000,000 (5)09/09/2035Common Stock2,000,000$02,000,000D(1)
    1. Name and Address of Reporting Person*
    Cohen Jacob D.

    (Last)(First)(Middle)
    C/O MANGOCEUTICALS, INC.
    17130 N. DALLAS PARKWAY, SUITE 240

    (Street)
    DALLAS TEXAS 75248

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    XDirectorX10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    1. Name and Address of Reporting Person*
    Tiger Cub Trust

    (Last)(First)(Middle)
    C/O MANGOCEUTICALS, INC.
    17130 N. DALLAS PARKWAY, SUITE 240

    (Street)
    DALLAS TEXAS 75248

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. Represents Mr. Cohen's direct ownership of the Issuer.
    2. Shares held directly by The Tiger Cub Trust, which is beneficially owned by Jacob D. Cohen, its Trustee. Mr. Cohen disclaims beneficial ownership of the securities held by The Tiger Cub Trust except to the extent of his pecuniary interest therein.
    3. On March 16, 2026, the Issuer's Board of Directors, with the recommendation and approval of the Compensation Committee of the Board of Directors, approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on March 16, 2026 (the "Effective Date") with a new exercise price of $0.45, which exceeded the closing price on Nasdaq as of the Effective Date. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
    4. A total of 1/3 of such options vested on each of September 1, 2023, 2024 and 2025.
    5. The options vest over 18 months with 500,000 of the options vesting upon grant on September 9, 2025, and 500,000 of the options vesting on the 6th, 12th, and 18th month anniversaries of the grant date, subject to Mr. Cohen's continued service with the Company on such vesting date; and vest in full upon any termination of Mr. Cohen by the Company without cause, or by Mr. Cohen for good reason, or upon a change of control of the Company.
    /s/ Jacob D. Cohen03/20/2026
    /s/ Jacob D. Cohen, Trustee, The Tiger Cub Trust03/20/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $MGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

    Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals," the "Company," or "MangoRx"), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has filed a civil lawsuit against Clarity Ventures, Inc., its former technology consulting and software development firm ("Clarity"). The lawsuit, filed in Texas state court, seeks damages exceeding $73 million, exclusive of interest, costs, and attorneys' fees. The Company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource plann

    3/17/26 4:00:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

    Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024. This PCT filing directly extends the intellectual property portfolio supporting the results

    3/6/26 4:00:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

    Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal, supports MGX-0024's potential to reduce respiratory disease impacts in commercial poultry settings and provide meaningful ea

    2/23/26 4:05:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    SEC Filings

    View All

    Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    3/17/26 4:00:33 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    2/23/26 4:05:40 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    2/19/26 4:05:51 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cohen Jacob D.

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    3/20/26 5:00:28 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 4 filed by Cohen Jacob D.

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    3/20/26 5:00:40 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    CFO Johnston Eugene M sold $3,884 worth of shares (3,333 units at $1.17), decreasing direct ownership by 3% to 120,000 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    12/17/25 5:00:28 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

    DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

    4/25/25 9:00:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Financials

    Live finance-specific insights

    View All

    Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

    Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

    12/19/24 5:33:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

    Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial

    8/15/24 9:25:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

    SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

    8/27/24 7:45:22 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

    SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

    6/5/24 5:15:19 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care